<DOC>
	<DOCNO>NCT02888652</DOCNO>
	<brief_summary>Study registration coronary heart disease patient undergoing PCI Chinese 's population . Get incidence adverse event patient PCI , clear type adverse reaction , form , influence factor , establish risk management process , clinical safety reasonable treatment , provide basis research reference .</brief_summary>
	<brief_title>Study Registration Coronary Heart Disease Patients Undergoing PCI</brief_title>
	<detailed_description>Dual antiplatelet therapy , comprise low-dose aspirin kind P2Y12 Receptor Inhibitors , mainstay management patient acute coronary syndrome and/or undergo Percutaneous Coronary Intervention ( PCI ) . While variability P2Y12 receptor inhibitor common patient major cause adverse cardiovascular event . Low response P2Y12 receptor inhibitor result high platelet reactivity ( HPR ) patient exhibit HPR increase risk atherothrombotic occlusion event . Vice versa , high response P2Y12 receptor inhibitor lead low platelet reactivity ( LPR ) increase risk hemorrhage.Now , absence universal definition therapeutic window different racial actual clinical situation lack gold standard test quantify limit use clinic practice.So clinical trial try use patient 's platelet reactivity combine type adverse reaction , form , influence factor find proper therapeutic window P2Y12 receptor inhibitor Chinese people .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Chinese 's patient diagnose coronary heart disease accept stent implantation . Accept aspirin P2Y12 receptor inhibitor ( clopidogrel ticagrelorwere）after stent implantation . Willingness ability sign inform consent . Can communicate effectively complete trial . Occurrence major complication procedure percutaneous coronary intervention platelet function test . Allergy intolerance aspirin P2Y12 receptor inhibitor ( clopidogrel ticagrelorwere）</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>PCI</keyword>
	<keyword>Anti-Platelet Agents</keyword>
</DOC>